FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

FDA Fast Track Designation for Berubicin highlights the serious unmet medical need for new treatments for glioblastoma multiforme (GBM) Company recently commenced enrollment in potentially pivotal study evaluating Berubicin in the treatment of adult rec... Biopharmaceuticals, Oncology, FDA CNS Pharmaceuticals, Berubicin, glioblastoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news